Log in

Relevant bibliographies by topics / Substance P

Academic literature on the topic 'Substance P'

Author: Grafiati

Published: 4 June 2021

Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Substance P.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Substance P"

1

Bernstein, Joel E. "Substance P and substance P antagonists." Current Opinion in Anaesthesiology 7, no. 5 (October 1994): 462–64. http://dx.doi.org/10.1097/00001503-199410000-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Snijdelaar, Dirk G., Ris Dirksen, Rob Slappendel, and Ben J. P. Crul. "Substance P." European Journal of Pain 4, no. 2 (June 2000): 121–35. http://dx.doi.org/10.1053/eujp.2000.0171.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Feighner, J. P. "Substance P." European Neuropsychopharmacology 8 (November 1998): S85. http://dx.doi.org/10.1016/s0924-977x(98)80054-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Harrison, S. "Substance P." International Journal of Biochemistry & Cell Biology 33, no. 6 (June 2001): 555–76. http://dx.doi.org/10.1016/s1357-2725(01)00031-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Iversen, Leslie. "Substance P equals pain substance?" Nature 392, no. 6674 (March 1998): 334–35. http://dx.doi.org/10.1038/32776.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Mecasermin/substance P." Reactions Weekly &NA;, no. 1050 (May 2005): 14. http://dx.doi.org/10.2165/00128415-200510500-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lowe, J. A. III. "Substance P antagonists." Drugs of the Future 17, no. 12 (1992): 1115. http://dx.doi.org/10.1358/dof.1992.017.12.194882.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Nanakida, Kunya, Dang Trang Nguyen, and Kozo Taguchi. "Synthesization and Photocatalytic Activity Evaluation of Float-Type g-C3N4 Microtubes." Defect and Diffusion Forum 428 (August 22, 2023): 119–23. http://dx.doi.org/10.4028/p-xnuv8q.

Full text

Abstract:

Float-type g-C3N4 microtubes were created by hydrothermal method and calcination using g-C3N4. Substances after hydrothermal synthesis and float-type g-C3N4 microtubes were investigated by XRD and SEM. The photocatalytic activity of float-type g-C3N4 microtubes was evaluated by methylene blue decomposition. According to these results, the substance, such as a needle, was found to have the same crystal structure as g-C3N4. In addition, it was confirmed that the needle-like substance was hollow inside, according to the SEM result. This substance can float on water. Therefore, Float type g-C3N4 microtubes can receive more light, and the decomposition rate has increased compared to g-C3N4.

APA, Harvard, Vancouver, ISO, and other styles

9

Jensen, Kai, Christian Tuxen, Ulrik Pedersen-Bjergaard, and Inger Jansen. "Pain, Tenderness, Wheal and Flare Induced by Substance-P, Bradykinin and 5-Hydroxytryptamine in Humans." Cephalalgia 11, no. 4 (September 1991): 175–82. http://dx.doi.org/10.1046/j.1468-2982.1991.1104175.x.

Full text

Abstract:

The algesic effect of substance-P with and without the addition of bradykinin or 5-hydroxytryptamine was studied in 13 healthy volunteers. Test substances dissolved in saline were injected into the temporal muscle and the forearm skin and the effects compared with those of saline. In the temporal muscle, none of the test substances induced more pain than saline, but substance-P with bradykinin lowered the pressure pain threshold by 18% ( p < 0.02). All test substances induced pain, wheal and flare in the forearm skin. Substance-P induced a more pronounced flare reaction than bradykinin, whereas the latter induced more pain than substance-P. This dissociation between pain and flare may indicate that C-fibres in the human skin represent more than one type of nociceptor.

APA, Harvard, Vancouver, ISO, and other styles

10

Kowall, N. W., B. J. Quigley, F. Lu, B. E. Kosofsky, and R. J. Ferrante. "Substance P and substance P receptor histochemistry in human neurodegenerative diseases." Regulatory Peptides 37 (September 1992): S27. http://dx.doi.org/10.1016/0167-0115(92)90883-v.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Substance P"

1

Kahn, Saima. "Neurochemical studies on substance P and substance P fragments in rat striatum." Thesis, Queen Mary, University of London, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.298358.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Garrett, Neil Edward. "Substance P and experimental joint inflammation." Thesis, Queen Mary, University of London, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.244679.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

McGregor, Gerard Patrick. "Radioimmunological studies of the physiology of substance P." Thesis, Imperial College London, 1985. http://hdl.handle.net/10044/1/37781.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Abdullah, L. H. "A radioimmunoassay for substance P : Biochemical and pathological studies." Thesis, Queen's University Belfast, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.373527.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Sandweiss, Alexander Jordan, and Alexander Jordan Sandweiss. "The Role of Substance P in Opioid Induced Reward." Diss., The University of Arizona, 2016. http://hdl.handle.net/10150/621568.

Full text

Abstract:

Chronic pain affects approximately 100 million Americans. Opioids are the mainstay therapy for the treatment of chronic pain. While physicians and patients alike are apprehensive about using opioids due to their side effects including respiratory depression and addiction, 259 million opioid prescriptions were written in 2012. Although opioids are the most efficacious available analgesics, they increase both positive and negative reinforcement, ultimately leading to addiction. The pro-nociceptive neurotransmitter, Substance P (SP) and its corresponding receptor (NK₁R), are not only found on pain pathways to promote pain but also found in the ventral tegmental area associated with dopamine neurons. Studies have shown that Substance P can potentiate positive reinforcement of opiates and may play a role in opioid reward. Here using in vivo microdialysis, we show that systemic morphine significantly increases SP release in the VTA, an effect mediated by ventral midbrain GABAergic neurons. Substance P administered to the VTA results in a significant increase in dopamine release in the nucleus accumbens (NAc). Using CRISPR-Cas9 knockdown of NK₁R in the VTA we prevent the induction of opiate reward as tested using a conditioned place preference paradigm (CPP). Finally, we developed a novel opioid agonist/NK₁R antagonist bifunctional compound, TY032, which inhibits acute and chronic pain in male rats. Importantly, TY032 microinjection into the VTA did not increase extracellular dopamine release in the NAc and did not produce a positive CPP score. These data indicate dual targeting of the dopamine reward circuitry and pain pathways with multifunctional opioid-NK₁R compounds may be an effective strategy in developing future analgesics that lack the potential for abuse.

APA, Harvard, Vancouver, ISO, and other styles

6

Wang, Linhong. "Differential processing of circulating substance P and neurokinin A /." The Ohio State University, 1995. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487862972134708.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Berthault, Béatrice. "Etude d'un systeme enzymatique membranaire degradant la substance p dans la substance noire chez le rat." Paris 6, 1988. http://www.theses.fr/1988PA066077.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Berthault, Béatrice. "Etude d'un système enzymatique membranaire dégradant la substance P dans la substance noire chez le rat." Grenoble 2 : ANRT, 1988. http://catalogue.bnf.fr/ark:/12148/cb37611893v.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Chui, Jeanie Jin Yee Medical Sciences Faculty of Medicine UNSW. "The role of substance P in the pathogenesis of pterygia." Publisher:University of New South Wales. Medical Sciences, 2007. http://handle.unsw.edu.au/1959.4/41503.

Full text

Abstract:

Pterygium is an ocular surface disorder characterised by centripetal invasion of the cornea by altered limbal cells, accompanied by fibrosis and neovascularisation. One of the enigmatic features of pterygium is its wing-like shape and the mechanism(s) supporting its centripetal growth remain to be elucidated. As the growth pattern of pterygia mirrors the radial arrangement of corneal nerves, we hypothesised that neuropeptides may facilitate its directional growth. In this thesis, we investigated the roles that the sensory neuropeptide substance P (SP) may play in the pathogenesis of pterygia given its known functions in corneal cell migration, proliferation, wound healing and neurogenic inflammation. Using a modified Boyden chamber method, SP was shown to act as a chemoattractant to pterygium fibroblasts and vascular endothelial cells, and this activity was diminish by blockade of its receptor (NK1). 3H-thymidine incorporation assays confirmed that our cell migration results were unrelated to SP-stimulated proliferation. A bead-based multiplex cytokine array detected secretion of pro-inflammatory cytokines (IL-6, IL-8 and CCL2) from SP stimulated pterygium and limbal epithelial cells. Using real-time RT-PCR and immunoblotting, we show that UVB stimulated transcription of the TAC1 gene followed by secretion of SP in ocular surface epithelial cell cultures. Finally, SP and NK1receptor immunoreactivity was identified in pterygium tissue, where overall, NK1receptors were up-regulated in pterygia. Furthermore, we identified a population of NK1 receptor positive mononuclear cells in pterygia that did not express lineage markers for T or B-Iymphocytes, macrophages or mast cells, but may represent immature haemopoietic cells that may have migrated in from the blood since these cells were also present in autologous conjunctival tissue. In summary, SP may contribute to the shape of pterygia by facilitating migration of fibroblasts and vascular endothelial cells into the normally avascular cornea. Additionally, UVB stimulates SP production in epithelial cells and the presence of SP contributes to inflammation in pterygia by inducing pro-inflammatory cytokine release. Finally, we identified a population of relatively immature, NK1 receptor positive cells in pterygia that may have been attracted by the presence of SP. Collectively, these results imply that SP may contribute to the pathogenesis of pterygia.

APA, Harvard, Vancouver, ISO, and other styles

10

Vetsika, Eleni-Kyriaki. "Actions of substance p on cellular responses during neurogenic inflammation." Thesis, Queen Mary, University of London, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.445300.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Substance P"

1

Henry, James L., Rejean Couture, A. Claudio Cuello, Georges Pelletier, Remi Quirion, and Domenico Regoli, eds. Substance P and Neurokinins. New York, NY: Springer New York, 1987. http://dx.doi.org/10.1007/978-1-4612-4672-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

C, Jordan C., and Oehme Peter, eds. Substance P: Metabolism and biological actions. London: Taylor & Francis, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

L, Henry J., International Union of Physiological Sciences. Congress, and IUPS Satellite Symposium "Substance P and Neurokinins - Montreal '86" (1986 : McGill University), eds. Substance P and neurokinins: Proceedings of "substance P and neurokinins--Montreal '86" : a satellite symposium of the XXX International Congress of the International Union of Physiological Sciences. New York: Springer-Verlag, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Iverfeldt, Kerstin. Release of coexisting neurotransmitters: In vitro studies on the release of the putative neurotransmitters serotonin, substance P and TRH from rat ventral spinal cord. Stockholm: University of Stockholm, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Placenza, Franca M. The involvement of substance P in relapse to cocaine-seeking behaviour in rats. Ottawa: National Library of Canada, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

McLean, Miriam. Five endogenous neuropeptides (dynorphin, endorphin, enkephalin, somatostatin, substance P) in nonhuman primates: A selected bibliography 1984-1992. Seattle, Wash: Primate Information Center, Regional Primate Research Center, University of Washington, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Alan, Johnson Robert, Hoffmann John P. 1962-, and Gerstein Dean R, eds. The relationship between family structure and adolescent substance use: By Robert A. Johnson, John P. Hoffmann, Dean R. Gerstein. Rockville, MD (5600 Fishers Lane, Rockville 20857): Substance Abuse and Mental Health Services Administration, Office of Applied Studies, U.S. Dept. of Health and Human Services, Public Health Service, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

United States. Agency for Toxic Substances and Disease Registry. Division of Toxicology. Dibenzo-p-dioxinas policloradas. Atlanta, GA]: Agencia para Sustancias Tóxicas y el Registro de Enfermedades, División de la Toxicología, Departamento de Salud y Servicios Humanos de los EE.UU., Servicio de Salud Pública, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Canada, Canada Environment, ed. Polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans: Scientific justification : candidate substances for management under track 1 of the Toxic Substances Management Policy. [Ottawa]: Environment Canada, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Verdonik, Daniel P. Strategic guidance and planning for eliminating ozone-depleting chemicals from U.S. Army applications: Prepared by Dr. Daniel P. Verdonik, Mr. Thomas A. Bush. [s.l.]: U.S. Army, Acquisition Pollution Prevention Support Office, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Substance P"

1

Snijdelaar, D. G., and R. Dirksen. "Substance P." In Pijn Info, 839–50. Houten: Bohn Stafleu van Loghum, 2004. http://dx.doi.org/10.1007/978-90-313-7316-1_152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Morgan, Michael M., MacDonald J. Christie, Luis De Lecea, Jason C. G. Halford, Josee E. Leysen, Warren H. Meck, Catalin V. Buhusi, et al. "Substance P." In Encyclopedia of Psychopharmacology, 1290. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1651.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Seth, John. "Substance P." In The Immunoassay Kit Directory, 361–64. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-1414-1_54.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Dun, Nae J. "Substance P." In Neurotransmitter Actions in the Vertebrate Nervous System, 385–410. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4684-4961-7_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Leeman, S. E. "Substance P and Neurokinins." In Substance P and Neurokinins, 1–2. New York, NY: Springer New York, 1987. http://dx.doi.org/10.1007/978-1-4612-4672-5_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Dobbins, D. E., M. J. Buehn, and J. M. Dabney. "Relative Vasodilatory Potencies of Substance P, Deca-Substance P and Nona-Substance P in the Canine Forelimb." In Substance P and Neurokinins, 161–63. New York, NY: Springer New York, 1987. http://dx.doi.org/10.1007/978-1-4612-4672-5_53.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bahrenberg, Gregor, and Corinna Maul. "Substance P/NK1 Receptors." In Analgesics, 519–41. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA, 2005. http://dx.doi.org/10.1002/3527605614.ch14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bodkin, Jennifer V., Gabor Pozsgai, Claire Sand, Rufino J. Klug, Thiago A. F. Ferro, and Elizabeth S. Fernandes. "Substance P in Inflammation." In Compendium of Inflammatory Diseases, 1221–27. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bodkin, Jennifer V., Gabor Pozsgai, Claire Sand, Rufino J. Klug, Thiago A. F. Ferro, and Elizabeth S. Fernandes. "Substance P in Inflammation." In Encyclopedia of Inflammatory Diseases, 1–8. Basel: Springer Basel, 2014. http://dx.doi.org/10.1007/978-3-0348-0620-6_11-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Deacon, C. F., and J. M. Conlon. "Biosynthesis of Substance P and Neurokinin A in the Enteric Nervous System." In Substance P and Neurokinins, 27–29. New York, NY: Springer New York, 1987. http://dx.doi.org/10.1007/978-1-4612-4672-5_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Substance P"

1

"SUBSTANCE USE AND PSYCHOPATHOLOGY IN THE PSYCHIATRIC CARE UNIT OF THE SOCIAL AFFAIRS SERVICE OF THE UNIVERSITY OF SALAMANCA." In 23° Congreso de la Sociedad Española de Patología Dual (SEPD) 2021. SEPD, 2021. http://dx.doi.org/10.17579/sepd2021p030v.

Full text

Abstract:

Introduction: University stage imply some changes and challenges that turn it into a crucial and tricky period for mental health and substance use. Material and methods: We present a study based on a sample of 49 people of the university community, 37 women and 12 men, evaluated in a seven months period. The assessment consisted in an interview carried out by a psychiatrist. A database was designed, providing the clinical information obtained from the interview and entry sheets during the first visit. Following descriptive and analytic studies were performed using the hypothesis contrast “Chi-Square” test. The reference statistical significance level was α = 0.05. Aims: To study the impact of substance use in the mental health of our sample in order to implement new prevention and treatment strategies. Results: 53,1% of the sample abuse substances: 30,8% men and 69,2% women (p 0,277). Alcohol is the most used substance in the sample (80,8%), followed by tobacco (57,7%) and cannabis (30,8%). Concerning psychopathology, insomnia (53,8%) is the most frequent symptom (p 0,260); thoughts of death were present in 46,2% of the substance users (p 0,419); while self-harm (p 0,365) and suicidal attempts (p 0,113) were described by the 19,2% of that group of the sample. Eating disorders and psychosis were observed in 23,1% (p 0,560) and 11,5% (p 0,743) respectively. Conclusions: Substance use is a very prevalent practice in our sample. We have observed some clinical symptoms are frequent in this part of the sample and we should pay special attention to their prevention and early treatment, as well as that of the substance use. This way we could minimize and tackle Mental Health problems in our sample.

APA, Harvard, Vancouver, ISO, and other styles

2

"DUAL PATHOLOGY: SUBSTANCE-RELATED DISORDERS: COMORBIDITIES." In 8th World Congress of the World Association of Dual Disorders (WADD) and the 26th Congress of the Spanish Society of Dual Disorders SEPD. SEPD/WADD, 2024. http://dx.doi.org/10.17579/abstractbookdualdisorders-p-077.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chockchai, K., and A. N. Cook. "Substance-Abuse Testing in Overseas E & P Operations." In SPE Health, Safety and Environment in Oil and Gas Exploration and Production Conference. Society of Petroleum Engineers, 1996. http://dx.doi.org/10.2118/35936-ms.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

"MINDFULNESS-BASED INTERVENTIONS FOR SUBSTANCE USE DISORDER." In 8th World Congress of the World Association of Dual Disorders (WADD) and the 26th Congress of the Spanish Society of Dual Disorders SEPD. SEPD/WADD, 2024. http://dx.doi.org/10.17579/abstractbookdualdisorders-p-296.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Del Rosso, A., L. Bertinotti, M. Messori, U. Pietrini, R. Sicuteri, A. Messori, M. Fanciullacci, and M. Matucci Cerinic. "FRI0195 Pupillocynetic activity of substance p in systemic sclerosis (ssc)." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

"O-007 - PRESCRIPTION PATTERNS ON PATIENTS WITH DUAL DIAGNOSIS: A RETROSPECTIVE INPATIENT ANALYSIS." In 24 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE PATOLOGÍA DUAL. SEPD, 2022. http://dx.doi.org/10.17579/abstractbooksepd2022.o007.

Full text

Abstract:

Introduction. Dual diagnosis (DD) refers to the simultaneous diagnosis of a psychiatric disorder and a substance use disorder (SUD). The prevalence rate is considerably high in patients with schizophrenia and affective disorders; it predicts a more severe illness course, with decreased adherence to treatment and higher rates of hospitalization. As such, there is a growing demand for clinical guidelines and treatment consensus for these patients. In this retrospective analysis, we aimed to examine if and how prescription patterns in DD differ regarding psychiatric diagnosis and type of substance used. Methods. Data from patients with a DD diagnosis admitted at Lisbon’s Psychiatric Hospital Center from June to September 2021 was collected (n=94). Chi-square or Fisher tests were used to analyze associations between substance use and specific psychiatric disorders, along with number and class of medications prescribed. Results. Schizophrenia was the most frequent diagnosis (n=47). The most abused substances were alcohol (n=62) and cannabinoids (n=57). We found a statistically significant association between schizophrenia and cannabis misuse (p=0,006). A personality disorder diagnosis was also found to be associated to the misuse of cannabinoids (p=0,04) and cocaine (p=0,003). Finally, there was a statistically significant association between prescription of 2 or more drugs from different classes and a diagnosis of schizophrenia. No association was found between number/class of drugs, other psychiatric conditions or the type of substance misuse. Conclusion. Our study confirms well established associations between specific substance use and psychiatric conditions. However, no evidence of a specific drug prescription pattern of use in DD patient was apparent, which suggests the need for more studies on DD population and treatment outcomes.

APA, Harvard, Vancouver, ISO, and other styles

7

Horak, Josef, Barbara Enderle, Huseyin Bakirci, and Gerald A. Urban. "Amperometric micro-immunosensor for rapid Substance-P quantification in biological fluids." In 2009 IEEE Sensors. IEEE, 2009. http://dx.doi.org/10.1109/icsens.2009.5398393.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lebold, Katie, Matthew Drake, Allison Fryer, Nancy Lee, James Lee, and David Jacoby. "Eosinophils impair degradation of airway substance P by inhibiting neutral endopeptidase." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa3916.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Otsuka, Kojiro, Akio Niimi, Hisako Matsumoto, Isao Ito, Masafumi Yamaguchi, Hirofumi Matsuoka, Makiko Jinnai, et al. "Plasma Substance P Levels In Patients With Subacute And Chronic Cough." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5905.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Drake, M. G., C. Shapiro, B. Proskocil, E. Blum, N. Kappel, C. Chang, A. Fryer, R. W. Costello, and D. Jacoby. "Airway Sensory Nerve Density and Substance P Is Increased in Chronic Cough." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a5610.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Substance P"

1

Witten, Mark L. The Role of Substance P in a Model of Chronic JP-8 Jet Fuel. Fort Belvoir, VA: Defense Technical Information Center, June 2000. http://dx.doi.org/10.21236/ada382194.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Weinberg, Zwi G., Richard E. Muck, Nathan Gollop, Gilad Ashbell, Paul J. Weimer, and Limin Kung, Jr. effect of lactic acid bacteria silage inoculants on the ruminal ecosystem, fiber digestibility and animal performance. United States Department of Agriculture, September 2003. http://dx.doi.org/10.32747/2003.7587222.bard.

Full text

Abstract:

The overall objective of the whole research was to elucidate the mechanisms by which LAB silage inoculants enhance ruminant performance. The results generated will permit the development of better silage inoculants that maximize both silage preservation and animal performance. For this one-year BARD feasibility study, the objectives were to: 1. determine whether lactic acid bacteria (LAB) used in inoculants for silage can survive in rumen fluid (RF) 2.select the inoculants that survived best, and 3. test whether LAB silage inoculants produce bacteriocins-like substances. The most promising strains will be used in the next steps of the research. Silage inoculants containing LAB are used in order to improve forage preservation efficiency. In addition, silage inoculants enhance animal performance in many cases. This includes improvements in feed intake, liveweight gain and milk production in 25-40% of studies reviewed. The cause for the improvement in animal performance is not clear but appears to be other than direct effect of LAB inoculants on silage fermentation. Results from various studies suggest a possible probiotic effect. Our hypothesis is that specific LAB strains interact with rumen microorganisms which results in enhanced rumen functionality and animal performance. The first step of the research is to determine whether LAB of silage inoculants survive in RF. Silage inoculants (12 in the U.S. and 10 in Israel) were added to clarified and strained RF. Inoculation rate was 10 ⁶ (clarified RF), 10⁷ (strained RF) (in the U.S.) and 10⁷, 10⁸ CFU ml⁻¹ in Israel (strained RF). The inoculated RF was incubated for 72 and 96 h at 39°C, with and without 5 g 1⁻¹ glucose. Changes in pH, LAB numbers and fermentation products were monitored throughout the incubation period. The results indicated that LAB silage inoculants can survive in RF. The inoculants with the highest counts after 72 h incubation in rumen fluid were Lactobacillus plantarum MTD1 and a L. plantarum/P. cerevisiae mixture (USA) and Enterococcus faecium strains and Lactobacillus buchneri (Israel). Incubation of rumen fluid with silage LAB inoculants resulted in higher pH values in most cases as compared with that of un-inoculated controls. The magnitude of the effect varied among inoculants and typically was enhanced with the inoculants that survived best. This might suggest the mode of action of LAB silage inoculants in the rumen as higher pH enhances fibrolytic microorganisms in the rumen. Volatile fatty acid (VFA) concentrations in the inoculated RF tended to be lower than in the control RF after incubation. However, L. plalltarull1 MTDI resulted in the highest concentrations of VFA in the RF relative to other inoculants. The implication of this result is not as yet clear. In previous research by others, feeding silages which were inoculated with this strain consistently enhanced animal performance. These finding were recently published in Weinberg et.al.. (2003), J. of Applied Microbiology 94:1066-1071 and in Weinberg et al.. (2003), Applied Biochemistry and Biotechnology (accepted). In addition, some strains in our studies have shown bacteriocins like activity. These included Pediococcus pentosaceus, Enterococcus faecium and Lactobacillus plantarum Mill 1. These results will enable us to continue the research with the LAB strains that survived best in the rumen fluid and have the highest potential to affect the rumen environment.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!